Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade. Hamidi H, Senbabaoglu Y, Beig N, Roels J, et al. Cancer Cell 2024;42:2098-2112.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hamidi H, Senbabaoglu Y, Beig N, Roels J, et al. Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade. Cancer Cell 2024;42:2098-2112.
PMID: 39577421